Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Apr 6 · below the Ichimoku cloud · RSI 21 (oversold) · MACD below its signal
None of the 29 investors followed here reported a position in ZVSA in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ZVSA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for ZVSA.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 19.4 | 62.5 | -23.1 | 5.5 | -2.8 | -22.0 | -36.9 | -2.0 | 3.0 | -55.9 | −66.4% | ||
| 2025 | 31.1 | -18.7 | -44.3 | -3.0 | 2.8 | 8.0 | -70.6 | -42.2 | 27.8 | -7.5 | 1.5 | -2.9 | −87.4% |
| 2024 | -36.7 | 93.0 | -31.8 | -29.5 | -6.6 | -23.9 | -8.0 | -20.2 | -13.0 | -16.3 | -46.6 | -1.3 | −88.2% |
| 2023 | 17.2 | 19.6 | -12.3 | -75.9 | -21.3 | -32.8 | -29.7 | -17.9 | -8.5 | -36.9 | -20.7 | -60.4 | −98.4% |
| 2022 | 0.8 | -0.1 | -0.1 | 0.0 | 0.3 | 0.2 | 0.1 | 0.4 | 1.3 | -84.5 | −84.1% |
No analyst coverage for this instrument.
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100 a humanized monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of numerous inflammatory diseases, with cardiometabolic conditions associated with obesity as the lead. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC. ZyVersa Therapeutics, Inc. was founded in 2014 and is based in Weston, Florida.
No recent headlines.